Browsing by Author "Enabor, O. O."

Now showing 1 - 3 of 3

Menstrual health of in-school adolescents in Ibadan: knowledge, attitudes and consequences
(Lagos Society for Advancement of Medical Education (SAME) Ventures, 2009) Owonikoko, K. M.; Okunlola, M. A.; Ogunbode, O. O.; Enabor, O. O.; Oluwasola, T. A. O.; Arowojolu, A. O.
We evaluated the knowledge, attitudes to and consequences of menstrual morbidities among in –school adolescents in Ibadan and determined their effect on school attendance. The pattern of drug use for menstrual symptoms was also assessed. Self-administered questionnaires were given to 1194 respondents in secondary schools chosen by randomization. The mean age of respondents was 15.7+ years while 86.1% were aged between 10-17 years. The most prevalent menstrual disorder was dysmenorrhea (87.3%). The commonest source of information about the menstrual cycle was from mothers (71%) while 0.5% of adolescents obtained information from health care givers. Menstrual symptoms were treated with non-pharmacological means in 53.1%. Of girls using pharmacologic agents 44% of them obtaining over the counter medications (OTC). Forty four percent of respondents missed school for 6-7 weeks per session following dysmenorrhea while 19% of them required hospital admission. It was concluded that there is insufficient knowledge of the menstrual cycle and its abnormalities among adolescents. Menstrual health should be introduced as part of reproductive health programs in school curricula in Nigeria.
Menstrual health of in-school adolescents in Ibadan: knowledge, attitudes and consequences
(2009) Owonikoko, K. M.; Okunlola, M. A.; Ogunbode, O. O.|; Enabor, O. O.; Oluwasola, T. A. O.; Arowojolu, A. O.
"We evaluated the knowledge, attitudes to and consequences of menstrual morbidities among in –school Adolescents in Ibadan and determined their effect on school attendance. The pattern of drug use for menstrual symptoms was also assessed. Self-administered questionnaires were given to 1194 respondents in secondary schools chosen by randomization. The mean age of respondents was 15.7+ years while 86.1% were aged between 10-17 years. The most prevalent menstrual disorder was dysmenorrhea (87.3%). The commonest source of information about the menstrual cycle was from mothers (71%) while 0.5% of adolescents obtained information from health care givers. Menstrual symptoms were treated with non-pharmacological means in 53.1%. Of girls using pharmacologic agents 44% of them obtaining over the counter medications (OTC). Forty four percent of respondents missed school for 6-7 weeks per session following dysmenorrhea while 19% of them required hospital admission. It was concluded that there is insufficient knowledge of the menstrual cycle and its abnormalities among adolescents. Menstrual health should be introduced as part of reproductive health programs in school curricula in Nigeria. "
Randomized controlled trial comparing 200 µg and 400 µg sublingual misoprostol for prevention of primary postpartum hemorrhage.
(2016) Ugwu, I. A.; Oluwasola, T. A. O.; Enabor, O. O.; Anayochukwu-Ugwu, N. N.; Adeyemi, A. B.; Olayemi, O. O.
Objective: To compare efficacy and adverse effects of 200 μg and 400μgmisoprostol for prevention of postpartum hemorrhage (PPH). Methods: In a randomized control trial, women with term singleton pregnancies in active labor attending University College Hospital, Ibadan, Nigeria, were enrolled between July 2011 and February 2012. Participants were randomly assigned using random numbers (block size four) to receive 200 μg or 400 μg sublingual misoprostol after delivery of the anterior shoulder, alongside intravenous oxytocin. Investigators were masked to group assignment, but participants were not. The primary outcomes were blood loss up to 1 h after delivery, PPH (blood loss ≥500 mL), and adverse effects. Results: Overall, 62 patients were assigned to each group. No significant differences between the 200-μg and 400-μg groups were recorded in mean per partum blood loss (307 ± 145 mL vs 296 ± 151 mL; P =0.679) and PPH occurrence (5 [8.1%] vs 6 [9.7%] women; P=0.752). Noticeable adverse effects were reported by 16 (25.8%) women in the 200-μg group and 42 (67.7%) in the 400-μg group (P b 0.001). Risk of shivering was significantly lower with 200 μg than 400 μg (relative risk 0.33, 95% confidence interval 0.19–0.58). Conclusion: Blood loss and PPH occurrence did not differ by misoprostol dose, but a 200-μg dose was associated with a reduction in adverse effects.